Thursday 30 November 2017

Free Research Reports on These Railroads Stocks -- Norfolk Southern, Trinity Industries, Union Pacific, and Westinghouse Air Brake Technologies

NEW YORK, Nov. 30, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on NSC, TRN, UNP, and WAB which is a click away at www.wallstequities.com/registration. Railroads are part of a broader Freight-Hauling industry that includes truckers, barge operators, and air transporters. The rails haul an estimated 15% of tonnage in America, a fraction of the 70% or so moved by truckers. Ahead of today's trading session, WallStEquities.com covers the recent performance of Norfolk Southern Corp. (NYSE: NSC), Trinity Industries Inc. (NYSE: TRN), Union Pacific Corp. (NYSE: UNP), and Westinghouse Air Brake Technologies Corp. (NYSE: WAB). Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at: www.wallstequities.com/registration

Norfolk Southern

Virginia-based Norfolk Southern Corp.'s stock finished Wednesday's session 4.81% higher at $136.41. A total volume of 3.63 million shares was traded, which was above their three months average volume of 1.41 million shares. Over the last month and the previous three months, the Company's shares have advanced 2.72% and 12.93%, respectively. Additionally, the stock has gained 26.22% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.64% and 12.27%, respectively. Moreover, shares of Norfolk Southern have a Relative Strength Index (RSI) of 65.14.

On November 01st, 2017, Norfolk Southern has released its 2017 corporate responsibility report, Strides in Stewardship, highlighting the railroad's progress in advancing sustainable freight transportation that benefits employees, customers, communities, suppliers, and shareholders. The Company's 10thannual sustainability report showed how it creates long-term value through sustainable business practices supporting the four pillars of its strategic plan: safety, service, stewardship of resources, and growth.

On November 27th, 2017, research firm Loop Capital downgraded the Company's stock rating from 'Hold' to 'Sell'. Free Access to this morning's research report on NSC at: www.wallstequities.com/registration/?symbol=NSC

Trinity Industries

Shares in Texas headquartered Trinity Industries Inc. rose 0.89%, ending yesterday's session at $35.29with a total trading volume of 1.20 million shares. The stock has gained 11.36% in the past month, 22.88% in the previous three months, and 27.13% on an YTD basis. The Company's shares are trading 6.77% above their 50-day moving average and 22.81% above their 200-day moving average. Moreover, shares of Trinity Industries have an RSI of 68.69.

On November 06th, 2017, research firm Susquehanna upgraded the Company's stock rating from 'Neutral' to 'Positive'.

On November 14th, 2017, Trinity Industries announced that earlier that day, the US Court of Appeals for the Fifth Circuit, in a per curiam order, denied the Relator's Petition for Rehearing En Banc in Joshua Harman, on behalf of the US, Plaintiff/Relator v. Trinity Industries, Inc. and Trinity Highway Products, LLC, Defendants. The Company will continue to monitor any pursuit by the Relator of further appellate recourse in this matter. Find your free research report TRN at: www.wallstequities.com/registration/?symbol=TRN

Union Pacific

On Wednesday, Nebraska headquartered Union Pacific Corp.'s stock climbed 3.48%, to close the day at $122.94. A total volume of 7.16 million shares was traded, which was above their three months average volume of 3.18 million shares. The Company's shares have advanced 5.65% in the last one month, 17.15% in the previous three months, and 18.58% on an YTD basis. The stock is trading 6.71% and 12.39% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Union Pacific have an RSI of 70.75.

On November 13th, 2017, research firm Goldman initiated a 'Sell' rating on the Company's stock, with a target price of $103 per share.

On November 16th, 2017, Union Pacific announced that its Board of Directors voted to increase the quarterly dividend on the Company's common shares by 10% to 66.5 cents per share. The increased dividend is payable on December 28th, 2017, to shareholders of record as of November 30th, 2017. Sign up today for the free research report on UNP at: www.wallstequities.com/registration/?symbol=UNP

Westinghouse Air Brake Technologies

Shares in Pennsylvania headquartered Westinghouse Air Brake Technologies Corp. ("Wabtec") ended the day 2.86% higher at $77.00. A total volume of 1.08 million shares was traded, which was above their three months average volume of 711,310 shares. The stock has gained 0.57% in the last one month and 9.34% in the previous three months. The Company's shares are trading above their 50-day moving average by 1.94%. Furthermore, shares of the Company have an RSI of 58.51.

On November 07th, 2017, Faiveley Transport, a subsidiary of Wabtec, has been awarded contracts worth more than $150 million by RailConnect NSW, a consortium consisting of the Hyundai Rotem Company, UGL Limited and Mitsubishi Electric Australia, to supply a complete range of railway systems and maintenance services for the 56 train sets (512 cars) of the New Intercity Fleet in New South Wales Australia. Sign up today for the free research report on WAB at: www.wallstequities.com/registration/?symbol=WAB

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

CONTACT: Tom Johnson, anewmedias@gmail.com

Modex Partners With BlockEx to Launch ICO Pre-sale for Smart Contract Marketplace

LONDON, Nov. 30, 2017 /PRNewswire/ -- Modex has announced that the ICO pre-sale for its smart contract marketplace will open today in partnership with BlockEx, a leader in blockchain digital asset exchange services, currently in an FCA innovation sandbox.

(Logo: http://mma.prnewswire.com/media/608924/BlockEx_Logo.jpg )

"We are thrilled to open the pre-sale," comments Modex, CEO, Mihai Ivascu, "and to partner with BlockEx - the best fit on the market to manage the entire lifecycle of blockchain-based digital assets."

Modex aims to bridge the gap between businesses and the growing community of creative developers, to accelerate the global adoption of blockchain technology. Given the emerging norm for 'borderless' transactions, distributed ledger technology has opened the door for a new world of data exchange, facilitated through smart contracts.

As organisations worldwide begin to grasp the vast benefits of blockchain, most are still struggling to implement and engage with the technology. "Given the major changes in a complex landscape such as payments, the adoption of blockchain technology comes with several challenges, notably integration concerns and high costs," Ivascu adds. "It is Modex's mission to offer a solution." Use-cases for companies and organisations applying blockchain technology are quickly growing and each well-implemented tech solution "is providing faster, cheaper transactions, with greater transparency and security," Modex's CEO told journalists.

The Modex ICO project aims to develop a blockchain-based ecosystem of solutions, addressing key use-cases to offer individuals and organisations an advanced scope of services.

BlockEx, CEO, Adam Leonard stated that his company "is pleased to partner with Modex; teaming up with Modex to fund and help develop a smart contract marketplace is truly exciting, as we understand that blockchain adoption has the ability to disrupt numerous industries."

About Modex

Modex is a Smart Contract Marketplace and app ecosystem that allows for easy, user-friendly access to crypto-currencies and smart contracts alike. Developers can leverage Modex to monetize their skills and offer smart contract solutions to end-customers and contributors. Modex makes deployment of smart contracts significantly easier, faster and more cost-effective, speeding up blockchain technology adoption.

About BlockEx

BlockEx's Digital Asset Platform (DAxP) is an institutional grade exchange with blockchain asset origination, dematerialisation and lifecycle management tools. The BlockEx DAxP includes a digital asset creation tool, exchange, clearing, settlement, registry and brokerage software. The offices are in London, Bulgaria, Taiwan and Israel. Visit https://www.blockex.com/.

Contact:
Adam Leonard
+44(0)203-637-5764

SOURCE BlockEx Ltd

THOMAS SABO is Getting in the Mood for Spring/Summer 2018 with the Tropical Series

LAUF AN DER PEGNITZ, Germany, Nov. 30, 2017 /CNW/ - Vivid jewellery colours, elaborately designed precious items and cultural diversity - for spring/summer 2018, THOMAS SABO is focusing on the iconic design language of the Sterling Silver Collection with an unprecedented intensity of colour. The style statements of the tropical-mythical motifs of the new Tropical series are special eye-catchers.

(Photo: http://mma.prnewswire.com/media/611819/THOMAS_SABO.jpg )

(Photo: http://mma.prnewswire.com/media/611821/Parrot_Pendant.jpg )

Filigree handcrafted statement pendants enchant as a highlight. The parrot and the sunstone amulet sparkle with their colours, Aztec-inspired patterns and filigree decoration. In addition, necklaces with swinging feathers as well as rings, earrings and bracelets impress in individual jewellery creations. The THOMAS SABO Snake fascinates for the first time as a ring, pendant, bangle or single earring in a green and turquoise look.

"Our Tropical series interprets the contrast between the dark green of the jungle, the colours of the animals and plants and sparkling light reflections in masterfully crafted jewellery creations," says Susanne Kölbli, Creative Director at THOMAS SABO.

The Tropical series, in addition to many other innovations from the Sterling Silver Collection, will be available in all THOMAS SABO shops and shop-in-shops, at http://www.thomassabo.com as well as from selected partners from mid-January 2018.

Image material is available to download for editorial purposes here.

About THOMAS SABO

THOMAS SABO is one of the globally-leading jewellery and watches companies, designing, selling and distributing lifestyle products for women and men. The company, established in 1984 by Thomas Sabo in Germany, operates around 300 of its own shops across all five continents with a total of 1,860 employees. THOMAS SABO also collaborates globally with approximately 2,800 trade partners as well as leading airlines and cruise operators.

SOURCE THOMAS SABO GmbH & Co.KG

CONTACT: Press contact: THOMAS SABO GmbH & Co. KG, Felizia Kindermann, Head of International & Corporate PR, +49912397150, press@thomassabo.com

Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors

CAMBRIDGE, Mass., Nov. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced the addition of George Demetri, M.D., a professor of medicine at Harvard Medical Schooland physician-scientist faculty member at the Dana-Farber Cancer Institute (DFCI), to its Board of Directors. Dr. Demetri, a world-renowned expert in the clinical translation of innovative treatment strategies for cancer, replaces John Mendelsohn, M.D., who is retiring from the Board.

"We are extremely pleased to add Dr. Demetri to our Board and know we will benefit enormously from his vast clinical development experience as we advance our deep clinical and preclinical pipeline of novel therapies for cancer," said Gary Crocker, Chairman of the Board of Merrimack. "We would like to thank Dr. Mendelsohn for his many contributions to our success since he joined the Merrimack Board in 2012, and are grateful for his invaluable insights."

Dr. Demetri leads a multidisciplinary team at the Dana-Farber/Harvard Cancer Center focused on developing novel therapies for solid tumors, with an emphasis on sarcomas. His research and clinical interests have centered on mechanism-based drug development for solid tumors, and he has contributed to the development of numerous approved therapies, including Gleevec (imatinib), Sutent (sunitinib), Stivarga (regorafenib), Zelboraf (vemurafenib) and Votrient (pazopanib), as well as other new targeted therapies in development. He received an undergraduate degree in biochemistry from Harvard University and an M.D. from Stanford University School of Medicine, after which he completed his residency in internal medicine at the University of Washington Hospitals in Seattle and a fellowship in medical oncology at DFCI. He also serves on the Board of Directors and Scientific Advisory Board of Blueprint Medicines (NASDAQ: BPMC).

"I am very excited for the opportunity to join the Merrimack Board and help the company fulfill its mission of outthinking cancer by targeting biomarker-defined cancers," said Dr. Demetri. "I believe that Merrimack is well-positioned to advance cancer care for patients in need through its focused approach to drug development."

About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of Merrimack's development programs, including four clinical studies and six candidates in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. For more information, please visit Merrimack's website at www.merrimack.com.

Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimackconstitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com

SOURCE Merrimack Pharmaceuticals, Inc.

Wednesday 29 November 2017

Greater New York Smiles Along With Colgate Bright Smiles, Bright Futures(R) And Baseball Great C.C. Sabathia Raise Oral Health Awareness Among Local Elementary School Children

Free Dental Screenings, Activities, Costumed Characters, and Celebrated Pitcher Help Underscore the Importance of Oral Health at Greater New York Dental Meeting

NEW YORK, Nov. 28, 2017 /PRNewswire/ -- Colgate Bright Smiles, Bright Futures teamed up with professional pitching ace C.C. Sabathia today to educate hundreds of local elementary school children on the importance of maintaining good oral health habits at the Greater New York Dental Meeting's Greater New York Smiles Program at the Jacob K. Javits Convention Center.

Against the backdrop of the largest dental meeting in the United States, Sabathia addressed the students, challenging them to think about oral health as an important part of their overall health and as a healthy habit that could have a major impact on their ability to perform in school and other arenas. The celebrated baseball star also led the students in a rousing cheer that reinforced the importance of healthy habits.

"Your family, teachers, and those of us here today all want you to have a future that you can smile about," Sabathia advised the students. "Listen closely to what you hear this morning, because all of you have the opportunity to be successful, and when you do, a healthy bright smile is going to come in handy."

During their visit to the Greater New York Dental Meeting, the New York City students boarded a Colgate mobile dental van for screenings performed by dental professionals. Volunteers from local hygienist schools staffed brushing stations, teaching the children proper brushing techniques, and oral health-themed videos, games, activity stations, puppets, and costumed characters encouraged the young guests to limit sugar and maintain an effective dental care routine.

Tooth decay is the most common chronic disease of childhood.¹ Left untreated, children with cavities may have difficulty eating, talking, and sleeping.² Oral health disease can also affect a child's attention span, school attendance, and academic performance, leading to significant implications for his or her social development and future success.³ A global oral health education initiative, Colgate Bright Smiles, Bright Futures has been raising oral health awareness among children for more than 25 years. Its fleet of nine mobile dental vans visit more than 1,000 U.S. cities and towns each year, providing free dental screenings, oral health education and treatment referrals, annually reaching nearly 10 million children.

"The importance of encouraging children to play a lead role in taking care of their teeth and gums cannot be overstated," said Dr. Marsha Butler, Vice President, Global Oral Health and Professional Relations, Colgate-Palmolive Company. "Oral health disease can be painful. It can be debilitating, but most important, it can be prevented. Someday soon we're hoping it's a challenge that none of our children have to face."

"The Greater New York Smiles program is a one of a kind program, because it gives back to the community without asking for anything in return," says Dr. Marc B. Gainor, General Chairman, Greater New York Dental Meeting. "It's a chance to offer a unique clinical experience to urban dental and hygiene students while bringing an awareness of dental access issues in NYC to oral healthcare volunteers, teachers and chaperoning parents who travel with the children to the Javits Convention Center."

ABOUT COLGATE-PALMOLIVE
Colgate-Palmolive is a leading global consumer products company, tightly focused on Oral Care, Personal Care, Home Care and Pet Nutrition. Colgate sells its products in over 200 countries and territories around the world under such internationally recognized brand names as Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom's of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill's Science Diet, Hill's Prescription Diet and Hill's Ideal Balance. For more information about Colgate's global business, visit the Company's web site at http://www.colgatepalmolive.com.

¹ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821841/
² https://www.mchoralhealth.org/PediatricOH/mod1_3.htm
³ https://www.medicaid.gov/medicaid/benefits/downloads/keep-kids-smiling.pdf

SOURCE Colgate-Palmolive Company

CONTACT: Tenley-Ann Hawkins, For Colgate Bright Smiles, Bright Futures, (914) 841-9717, thawks812@msn.com; Colgate-Palmolive Company, Media Relations, (212) 310-2670, Colgate-Palmolive_Media_Inquiry@colpal.com

RELATED LINKS
http://www.colgatepalmolive.com

CytoSorbents to Present at the LD Micro Main Event Investor Conference

MONMOUTH JUNCTION, N.J., Nov. 29, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to prevent or treat life-threatening injury and infection in critically-ill and cardiac surgery patients around the world, will present at the 10^th Annual LD Micro Main Event investor conference held from December 5-7^th, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Dr. Phillip Chan, Chief Executive Officer at CytoSorbents, will also participate in one-on-one meetings, made by appointment, with investors who are registered to attend the conference.

Date:	Tuesday, December 5, 2017
Time:	10:30AM PST (1:30PM EST)
Location:	Luxe Sunset Boulevard Hotel, Los Angeles, CA
Webcast:	http://wsw.com/webcast/ldmicro13/ctso/

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature over 200 presenting names. In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. For more information, please visit http://www.ldmicro.com/events.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 44 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety and efficacy of free hemoglobin reduction with intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 31,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $21 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, K⁺ontrol™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

CytoSorbents Contact:
Amy Vogel
Investor Relations
732-398-5394
avogel@cytosorbents.com

Investor Relations Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

Public Relations Contact:
Joshua Berkman
Rubenstein Public Relations
212-805-3055
jberkman@rubensteinpr.com

SOURCE CytoSorbents Corporation

Special Delivery: Domino's(R) Launches Baby Registry

Introducing a baby registry for pizza-loving parents

ANN ARBOR, Mich., Nov. 29, 2017 /PRNewswire/ -- Domino's Pizza (NYSE: DPZ) is preparing for another great delivery. Starting today, the recognized world leader in pizza delivery is sending out birth announcements for its latest labor of love – a baby registry powered by Gugu Guru. Parents-to-be can create their own registry at dominosbabyregistry.com.

"There's nothing more exciting – and exhausting – than welcoming a new member to the family," said Meenakshi Nagarajan, Domino's director of digital marketing. "From baby showers to the big delivery, our baby registry makes it easy to enjoy pizza during the exciting events leading up to the baby's arrival and thereafter."

After creating and customizing their registry, parents can choose from a variety of gift card themes to use before and after their little ones' arrival. For instance, customers can shower expectant moms and dads with the gift of pizza at their gender reveal party, or allow them savor one last bite before baby. All gifts will be delivered to the parents-to-be as Domino's eGift cards.

"Earlier this year we introduced Domino's wedding registry, which was extremely well-received by our customers," said Nagarajan. "Introducing a baby registry was a natural progression. In fact, our baby registry is making its debut exactly nine months later."

One lucky person will win free pizza for a year and several other pizza-themed gifts such as onesies, leggings, moccasins, and mugs from Gugu Guru by entering on their blog or via the widget displayed on the Gugu Guru Facebook page.

Once registrants select their gifts, they can share their wish list with family and friends on social media or with a unique URL.

Know pizza-loving parents who aren't registered? You can still give them a gift! Find more information about Domino's baby registry at dominosbabyregistry.com.

Open to legal residents of USA who are 18 years or older. Void where prohibited or restricted by law. NO PURCHASE NECESSARY TO ENTER OR WIN. A PURCHASE DOES NOT IMPROVE YOUR CHANCES OF WINNING. Ends 12/29/17. To enter and for Official Rules, visit http://blog.guguguru.com/dominos.

About Domino's Pizza^®Founded in 1960, Domino's Pizza is the recognized world leader in pizza delivery, with a significant business in carryout pizza. It ranks among the world's top public restaurant brands with a global enterprise of more than 14,400 stores in over 85 international markets. Domino's had global retail sales of nearly $10.9 billion in 2016, with more than $5.3 billion in the U.S. and more than $5.5 billioninternationally. In the third quarter of 2017, Domino's had global retail sales of more than $2.8 billion, with nearly $1.4 billion in the U.S. and over $1.4 billion internationally. Its system is comprised of independent franchise owners who accounted for over 97% of Domino's stores as of the third quarter of 2017. Emphasis on technology innovation helped Domino's reach an estimated $5.6 billion in global digital sales in 2016, and has produced several innovative ordering platforms, including Google Home, Facebook Messenger, Apple Watch, Amazon Echo, Twitter and text message using a pizza emoji. In late 2017, as part of an industry-first collaboration with Ford Motor Company, Domino's began a meaningful test of delivery using self-driving vehicles.

Order – dominos.com
AnyWare Ordering – anyware.dominos.com
Company Info – biz.dominos.com
Twitter – twitter.com/dominos
Facebook – facebook.com/dominos
Instagram – instagram.com/dominos
YouTube – youtube.com/dominos

Please visit our Investor Relations website at biz.dominos.com to view news, announcements, earnings releases and conference webcasts.

About Gugu Guru
Launched in April of 2015, Gugu Guru is the first and only universal baby registry to deliver free, unbiased and highly personalized product recommendations for expectant and new parents based on their answers to a fun style and lifestyle quiz.

SOURCE Domino's Pizza

CONTACT: Jenny Fouracre, 734-930-3620 (Office), jenny.fouracre@dominos.com

KIND And Mars Announce Partnership To Bring Healthy Snacks And The KIND Promise To People Worldwide

NEW YORK and MCLEAN, Va., Nov. 29, 2017 /PRNewswire/ -- KIND, a healthy snacking leader, and Mars, Incorporated, a family-owned global pet care, confectionery and food business, today announced a strategic partnership whereby Mars will take a minority stake in KIND. As part of the agreement, the two companies will partner to grow KIND's product offerings and business globally, utilizing each other's strengths.

The partnership will allow KIND to continue to drive positive change in the food industry while fulfilling – on a worldwide scale – its KIND Promise, a set of nutrition principles that have guided the company's innovation since its founding. KIND will provide Mars with a pioneering and trusted brand to anchor a newly formed global health and wellness platform, while Mars will provide KIND with its proven international model to expand into new markets. KIND will continue to operate independently, led by its majority stakeholders, founder Daniel Lubetzky and the KIND team, with its existing headquarters in New York, NY. As part of the agreement, Mars will lead the growth of the business outside the U.S. and Canada, partnering with KIND in accordance with the KIND Promise.

The partnership will enable KIND to accelerate its dual mission to make its healthy and tasty foods available to more people across the globe and make the world a little kinder through meaningful social impact initiatives. It will also enable KIND to expand into new categories.

"When we introduced our first whole nut & fruit bar in 2004, we set out on an ambitious mission to do things differently and challenge false compromises by offering snacks that were healthy and tasty as well as wholesome and convenient. It's been exciting to see the reach and impact of our mission, and with our partnership with Mars, we're looking forward to continuing on this journey as we empower more people to make healthy eating decisions across the globe. We remain fully committed to our guiding principles, including our commitment to always use a nutritious food as the first and predominant ingredient in every food product," said Daniel Lubetzky, Founder and CEO of KIND. "We're proud to partner with Mars, a family-owned, principles-driven company with a proven track record of holding a long-term view, and look forward to working with them to make this a better world for future generations."

"This is a partnership built on mutual admiration and a shared vision for growth," said Grant F. Reid, CEO and President of Mars. "We believe there is tremendous opportunity to build on the success of KIND's product portfolio in new markets. As we continue to expand our business and broaden our portfolio to address evolving consumer needs, we're delighted to partner with a respected leader in the health & wellness space."

Every day millions of people do the KIND thing for their bodies by eating KIND's snacks. As KIND continues to expand, it will fulfill its KIND Promise by:

Always using a nutritious food as the first and predominant ingredient in every food product;
Never using artificial sweeteners or sugar alcohols;
Using as little sugar as possible while achieving great taste;
Creating foods that are both healthy and tasty;
Being transparent about everything from ingredients to labeling;
Crafting foods made with minimally processed, real ingredients; and
Treating its foods and people with integrity.

The partnership will also empower KIND to scale its social mission and fulfill its vision to use business as a vehicle for social change. In that spirit, Daniel Lubetzky plans to donate $25 million to The KIND Foundation, a separate philanthropic entity that aims to foster kinder and more empathetic communities.

To learn more, visit www.kindsnacks.com/partnership.

Advisors

BDT & Company and Centerview Partners served as KIND's financial advisors, and Goodwin Procter LLP acted as KIND's legal advisor.

Morgan Stanley & Co. LLC served as Mars' financial advisor, and Simpson Thacher & Bartlett LLP acted as Mars' legal advisor.

About KIND

Since its founding in 2004, KIND® has been on a mission to make the world a little kinder one snack and one act at a time. KIND was born out of its founder's desire to create a snack that was healthy and tasty, wholesome and convenient. What began as a line of premium Fruit & Nut bars sparked the creation of an entirely new healthier snacking category. Today, KIND has a family of snacks that offer solutions for a variety of different occasions.

Its recipes include nutrient-dense, simple and premium ingredients like whole nuts, seeds, whole grains, and pieces of fruit. All of its snacks are gluten free and do not contain genetically engineered ingredients.

Since day one, kindness has been at the core of its business. KIND was founded with a social mission, called the KIND Movement, which celebrates and inspires kindness through acts big and small. Today, the Movement is brought to life through both the brand and The KIND Foundation. To learn more about KIND and to join our Movement, visit kindsnacks.com or follow along on social media @kindsnacks.

About Mars

Mars is a family-owned business with more than a century of history making diverse products and offering services for people and the pets people love. With almost $35 billion in sales, the company is a global business that produces some of the world's best-loved brands: M&M's®, SNICKERS®, TWIX®, MILKY WAY®, DOVE®, PEDIGREE®, ROYAL CANIN®, WHISKAS®, EXTRA®, ORBIT®, 5™, SKITTLES®, UNCLE BEN'S®, MARS DRINKS and COCOAVIA®. Mars also provides veterinary health services that include BANFIELD® Pet Hospitals, Blue Pearl®, VCA® and Pet Partners™. Headquartered in McLean, VA, Mars operates in more than 80 countries. The Mars Five Principles – Quality, Responsibility, Mutuality, Efficiency and Freedom – inspire its more than 100,000 Associates to create value for all its partners and deliver growth they are proud of every day.

For more information about Mars, please visit www.mars.com. Join us on Facebook, Twitter, LinkedIn, Instagram and YouTube.

About The KIND Foundation

The KIND Foundation is a philanthropic entity established by KIND. Its mission, which is to foster kinder and more empathetic communities, is brought to life through a variety of programming meant to celebrate and inspire positive action. The Foundation recently announced a $20 million multi-year initiative called Empatico. An online learning tool that connects kids worldwide and helps them develop skills like curiosity and kindness, Empatico endeavors to reach more than one million students by the end of 2020. To learn more, visit kindsnacks.com/foundation.

SOURCE KIND

CONTACT: Brunswick Group: Jayne Rosefield, 312-800-8120; Blake Sonnenshein, 212-333-3810; KIND: Drew Nannis, 202-236-7016